Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785636 | 0.96 | ACHE (0.42) | F10MCHR1ACHECCR5POLB | |
| SCHEMBL784886 | 0.89 | F10 (0.41) | F10ACHEPOLBJAK2JAK1 | |
| SCHEMBL28805786 | 0.88 | ACHE (0.46) | F10MCHR1ACHECCR5POLB | |
| SCHEMBL785875 | 0.87 | MCHR1 (0.39) | F10MCHR1CCR5POLBROCK2 | |
| SCHEMBL785091 | 0.86 | ACHE (0.43) | F10MCHR1ACHECCR5POLB | |
| SCHEMBL785282 | 0.85 | ACHE (0.41) | F10ACHEPOLBJAK2JAK1 | |
| SCHEMBL786234 | 0.85 | CCR5 (0.40) | F10MCHR1CCR5POLBROCK2 | |
| SCHEMBL784410 | 0.83 | POLB (0.41) | F10MCHR1ACHECCR5POLB | |
| SCHEMBL784304 | 0.83 | POLB (0.42) | F10MCHR1ACHECCR5POLB | |
| SCHEMBL784767 | 0.82 | MCHR1 (0.38) | F10MCHR1CCR5POLBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885MCHR1 363/4885ACHE 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.